99 related articles for article (PubMed ID: 7371023)
21. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
Stewart DJ; Leavens M; Friedman J; Benjamin RS; Moore EC; Bodey GP; Valdivieso M; Burgess MA; Wiseman C; Loo TL
Cancer Res; 1980 Sep; 40(9):3163-6. PubMed ID: 7427934
[TBL] [Abstract][Full Text] [Related]
22. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
[TBL] [Abstract][Full Text] [Related]
23. Aspartate transcarbamylase (ATCase) of Escherichia coli: a new crystalline R-state bound to PALA, or to product analogues citrate and phosphate.
Huang J; Lipscomb WN
Biochemistry; 2004 Jun; 43(21):6415-21. PubMed ID: 15157075
[TBL] [Abstract][Full Text] [Related]
24. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
Grant S; Rauscher F; Jakubowski A; Cadman E
Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
[TBL] [Abstract][Full Text] [Related]
25. 13C isotope effect studies of Escherichia coli aspartate transcarbamylase in the presence of the bisubstrate analog N-(phosphonoacetyl)-L-aspartate.
Parmentier LE; O'Leary MH; Schachman HK; Cleland WW
Biochemistry; 1992 Jul; 31(28):6598-602. PubMed ID: 1633172
[TBL] [Abstract][Full Text] [Related]
26. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
27. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
Baillon J; Guichard M; Malaise EP; Hervé G
Cancer Res; 1983 May; 43(5):2277-82. PubMed ID: 6831451
[TBL] [Abstract][Full Text] [Related]
28. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Chan TC; Markman M; Cleary S; Howell SB
Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
[TBL] [Abstract][Full Text] [Related]
29. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
30. Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
Strong JM; Kinney YE; Branfman AR; Cysyk RL
Cancer Treat Rep; 1979 May; 63(5):775-80. PubMed ID: 455314
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Johnson RK; Inouye T; Goldin A; Stark GR
Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
[TBL] [Abstract][Full Text] [Related]
34. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
Grant S; Rauscher F; Cadman E
Cancer Res; 1982 Oct; 42(10):4007-13. PubMed ID: 6955007
[TBL] [Abstract][Full Text] [Related]
35. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
[TBL] [Abstract][Full Text] [Related]
36. N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Rozencweig M; Abele R; Piccart M; Von Hoff DD; Muggia FM
Recent Results Cancer Res; 1980; 74():72-7. PubMed ID: 7444151
[TBL] [Abstract][Full Text] [Related]
37. Gross quaternary changes in aspartate carbamoyltransferase are induced by the binding of N-(phosphonacetyl)-L-aspartate: A 3.5-A resolution study.
Ladner JE; Kitchell JP; Honzatko RB; Ke HM; Volz KW; Kalb AJ; Ladner RC; Lipscomb WN
Proc Natl Acad Sci U S A; 1982 May; 79(10):3125-8. PubMed ID: 6954462
[TBL] [Abstract][Full Text] [Related]
38. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Johnson RK; Swyryd EA; Stark GR
Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
[No Abstract] [Full Text] [Related]
39. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
[TBL] [Abstract][Full Text] [Related]
40. m-AMSA and PALA: two new agents in cancer chemotherapy.
Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM
Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]